1. Home
  2. VATE vs KLRS Comparison

VATE vs KLRS Comparison

Compare VATE & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo INNOVATE Corp.

VATE

INNOVATE Corp.

HOLD

Current Price

$7.68

Market Cap

103.5M

Sector

Industrials

ML Signal

HOLD

Logo Kalaris Therapeutics Inc.

KLRS

Kalaris Therapeutics Inc.

HOLD

Current Price

$3.12

Market Cap

92.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VATE
KLRS
Founded
1994
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
103.5M
92.8M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
VATE
KLRS
Price
$7.68
$3.12
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$19.00
AVG Volume (30 Days)
93.8K
52.1K
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
75.70
EPS
N/A
N/A
Revenue
$1,246,000,000.00
$165,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
12.55
N/A
52 Week Low
$3.75
$3.03
52 Week High
$21.30
$11.88

Technical Indicators

Market Signals
Indicator
VATE
KLRS
Relative Strength Index (RSI) 52.97 N/A
Support Level $6.48 N/A
Resistance Level $8.20 N/A
Average True Range (ATR) 0.48 0.00
MACD 0.20 0.00
Stochastic Oscillator 88.28 0.00

Price Performance

Historical Comparison
VATE
KLRS

About VATE INNOVATE Corp.

Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments. Its segments include Infrastructure, Life Sciences and Spectrum, and Other segment. Through its subsidiaries it provides fully integrated structural and steel construction services; supports healthcare and biotechnology product development; and operates Over-The-Air (OTA) broadcasting stations across the United States (U.S.) including Puerto Rico.

About KLRS Kalaris Therapeutics Inc.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Share on Social Networks: